JP2016513687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513687A5 JP2016513687A5 JP2016502354A JP2016502354A JP2016513687A5 JP 2016513687 A5 JP2016513687 A5 JP 2016513687A5 JP 2016502354 A JP2016502354 A JP 2016502354A JP 2016502354 A JP2016502354 A JP 2016502354A JP 2016513687 A5 JP2016513687 A5 JP 2016513687A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heteroalkyl
- amino
- alkoxy
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- 102000003621 TRPC5 Human genes 0.000 claims description 8
- 101150042815 TRPC5 gene Proteins 0.000 claims description 8
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims 16
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 14
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 10
- 125000004754 (C2-C12) dialkylamino group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 7
- 150000001408 amides Chemical class 0.000 claims 6
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 6
- 125000004104 aryloxy group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001624 naphthyl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 229940100389 Sulfonylurea Drugs 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000005864 sulfonamidyl group Chemical group 0.000 claims 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 3
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 claims 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229940125684 antimigraine agent Drugs 0.000 claims 1
- 239000002282 antimigraine agent Substances 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 150000005599 propionic acid derivatives Chemical class 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- 0 CN(c1c(C(N2C)=O)[n](*)c(*)n1)C2=O Chemical compound CN(c1c(C(N2C)=O)[n](*)c(*)n1)C2=O 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784448P | 2013-03-14 | 2013-03-14 | |
| US61/784,448 | 2013-03-14 | ||
| PCT/US2014/027166 WO2014152287A2 (en) | 2013-03-14 | 2014-03-14 | Substituted xanthines and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513687A JP2016513687A (ja) | 2016-05-16 |
| JP2016513687A5 true JP2016513687A5 (enExample) | 2017-07-13 |
Family
ID=50819943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502354A Withdrawn JP2016513687A (ja) | 2013-03-14 | 2014-03-14 | 置換キサンチンおよびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140275528A1 (enExample) |
| EP (1) | EP2970316B1 (enExample) |
| JP (1) | JP2016513687A (enExample) |
| AR (1) | AR095561A1 (enExample) |
| TW (1) | TW201444844A (enExample) |
| UY (1) | UY35424A (enExample) |
| WO (1) | WO2014152287A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016023831A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
| WO2016086008A1 (en) * | 2014-11-26 | 2016-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Small molecule aldehyde dehydrogenase inhibitors and methods of use thereof |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| WO2018157800A1 (en) * | 2017-02-28 | 2018-09-07 | National Institute Of Biological Sciences, Beijing | Mlkl inhibitors |
| GB201712110D0 (en) * | 2017-07-27 | 2017-09-13 | Thomas Helledays Stiftelse För Medicinsk Forskning | New compounds and uses |
| CA3075727A1 (en) * | 2017-09-18 | 2019-03-21 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| US11623930B2 (en) | 2018-03-05 | 2023-04-11 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
| US20220152031A1 (en) * | 2019-03-20 | 2022-05-19 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| CN113603690B (zh) * | 2021-08-02 | 2022-10-25 | 南开大学 | 一种含黄嘌呤-8-基的(e)-丙烯酸衍生物及其制备方法和应用 |
| CN115636831B (zh) * | 2022-10-27 | 2024-11-08 | 中国药科大学 | 稠合嘧啶二酮类化合物、其用途以及药物组合物 |
| CN116023336A (zh) * | 2022-12-13 | 2023-04-28 | 河北医科大学 | 一种具有Nav1.7钠离子通道靶向抑制作用的化合物及其药物组合物和用途 |
| CN116217575B (zh) * | 2023-01-09 | 2025-01-10 | 广东赛烽医药科技有限公司 | 一种8-溴茶碱的制备方法 |
| CN118459461A (zh) * | 2023-02-08 | 2024-08-09 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090018148A1 (en) * | 2005-12-07 | 2009-01-15 | Ucb Pharma, S.A. | Xanthine Derivatives, Processes For Preparing Them And Their Uses |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
-
2014
- 2014-03-13 TW TW103108996A patent/TW201444844A/zh unknown
- 2014-03-13 UY UY0001035424A patent/UY35424A/es not_active Application Discontinuation
- 2014-03-14 WO PCT/US2014/027166 patent/WO2014152287A2/en not_active Ceased
- 2014-03-14 EP EP14726452.7A patent/EP2970316B1/en not_active Not-in-force
- 2014-03-14 US US14/210,666 patent/US20140275528A1/en not_active Abandoned
- 2014-03-14 JP JP2016502354A patent/JP2016513687A/ja not_active Withdrawn
- 2014-03-17 AR ARP140101183A patent/AR095561A1/es unknown
-
2016
- 2016-01-30 US US15/011,523 patent/US20160145257A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513687A5 (enExample) | ||
| JP2016513717A5 (enExample) | ||
| EA201890888A1 (ru) | Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53 | |
| WO2017040993A4 (en) | Small molecule inhibitors of dyrk1a and uses thereof | |
| JP2016528301A5 (enExample) | ||
| JO3407B1 (ar) | مركبات رباعي هيدرو بيرازولو بيريميدين | |
| HRP20201216T1 (hr) | PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a | |
| MA35941B1 (fr) | Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale | |
| JP2018531891A (ja) | Ｂｅｔブロモドメインインヒビターに対する抵抗性の機構 | |
| JP2017517538A5 (enExample) | ||
| JP2015521156A5 (enExample) | ||
| JP2015500223A5 (enExample) | ||
| EP3402477A2 (en) | Methods for the treatment of myeloid derived suppressor cells related disorders | |
| RU2017141001A (ru) | Производные 1,4-бензодиазепин-2-она и их применение | |
| JP2016535040A5 (enExample) | ||
| JP2016515550A5 (enExample) | ||
| SA521421997B1 (ar) | مركب 1، 3، 4-أكسا ديازولون ومستحضر صيدلاني | |
| CL2018000339A1 (es) | Tratamiento de combinación que comprende la administración de 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas. | |
| AR078537A1 (es) | Derivados heterociclicos de indol ligandos del receptor de estrogenos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades asociadas al sistema nervioso central, osteoporosis, canceres y otras patologias | |
| WO2018222975A1 (en) | Methods for the treatment of cancer | |
| JP2017537157A5 (enExample) | ||
| SI3006443T1 (en) | THE BENZOIOFENE COMPOUNDS | |
| TH1801006379A (th) | ตัวยับยั้งโบรโมโดเมน | |
| HK1242201A1 (en) | Compositions and methods for treating cns disorders | |
| TH1701000793A (th) | สารประกอบไพร์โรโลไพริมิดีนซึ่งถูกใช้ในฐานะเป็นตัวทำการtlr7 |